Lilly and Pfizer have invested in a $31 million seed funding round for Trimtech Therapeutics, a UK-based startup developing protein degraders to treat neurodegenerative diseases. Cambridge Innovation Capital co-led the £25 million round, which also included investments from the Dementia Discovery Fund, M Ventures, Cambridge Enterprise Ventures, Start Codon, and MP Healthcare Venture Management. Trimtech’s pipeline focuses on creating treatments for diseases such as Alzheimer’s and Huntington’s using Trimtac degrader molecules.
These molecules target protein aggregates associated with various neurodegenerative conditions. Nicola Thompson, CEO of Trimtech Therapeutics, expressed enthusiasm about the potential impact of their innovative approach.
Neurodegenerative disease therapy advancements
“We are thrilled to have the support of Lilly and Pfizer as we work towards developing therapies that could significantly improve the lives of patients suffering from these debilitating conditions,” Thompson stated. The company was founded by CIC and DDF in collaboration with entrepreneur-in-residence Damian Crowther and academic co-founders Leo James from the MRC Laboratory of Molecular Biology and Will McEwan from the UK Dementia Research Institute at the University of Cambridge. Trimtech has also expanded its board of directors with recent appointments, including Michael Anstey from Cambridge Innovation Capital, Laurence Barker from SV Health Investors, M Ventures Managing Director Hakan Goker, MP Healthcare Venture Management President Jeffrey Moore, and Pfizer Ventures’ Marie-Claire Peakman.
The financial backing from renowned industry leaders underscores the growing interest and investment in the field of neurodegenerative disease treatment and the promise of protein degrader technology. This significant seed round investment will enable Trimtech to accelerate its research and development efforts, bringing new hope to the field of neurodegeneration. With over 55 million people affected by Alzheimer’s and millions more battling other neurodegenerative disorders, Trimtech’s groundbreaking innovation has the potential to transform the course of treatment for these patients.
Photo by; mike_ramirez_mx on Pixabay
